Timing of eculizumab therapy for C3 glomerulonephritis

Eculizumab is an anti-C5 antibody that inhibits C5 cleavage and prevents the generation of the terminal complement complex C5b-9. Eculizumab is licensed to treat paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome (aHUS). Clinical trials are ongoing for C3 glomerulopathy. Gi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Osorio, Laura, Ortiz, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Contents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515909/
https://www.ncbi.nlm.nih.gov/pubmed/26251715
http://dx.doi.org/10.1093/ckj/sfv065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515909/
https://www.ncbi.nlm.nih.gov/pubmed/26251715
http://dx.doi.org/10.1093/ckj/sfv065

Ejemplares similares